A Combined Surgical and Medical Approach in Mild Sleep Apnea

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by University Hospital, Antwerp.
Recruitment status was  Recruiting
Information provided by:
University Hospital, Antwerp
ClinicalTrials.gov Identifier:
First received: July 4, 2007
Last updated: July 5, 2007
Last verified: July 2007
The aim of the study is to investigate wether the adjuvant (postoperative) administration of acetazolamide can improve the surgical results after uvulopalatopharyngoplasty in patients with mild sleep apnea.

Condition Intervention
Sleep Apnea
Drug: acetazolamide
Drug: placebo
Procedure: uvulopalatopharygoplasty

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University Hospital, Antwerp:

Primary Outcome Measures:
  • Polysomnographic parameters

Secondary Outcome Measures:
  • subjective sleepiness
  • subjective snoring
  • satisfaction


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 5 ≤ Apnea Hypopnea Index (AHI) < 20
  • Socially disturbing snoring: Visual Analogue Scale (VAS)snoring > 6/10
  • Based on clinical examination and polysomnography, patient is regarded eligible for uvulopalatopharyngoplasty (UPPP)

Exclusion Criteria:

  • Previous surgical treatment for sleep-disordered breathing.
  • Periodic Limb Movement Disorder (PLMD) with arousals and other reasons possibly explaining the Excessive Daytime Sleepiness (EDS) based on Epworth Sleepiness Scale (ESS).
  • Forced expiratory volume in 1 second (FEV1) < 80 % pred.
  • Echocardiography: ejectionfraction < 35 % or dyastolic dysfunction grade 2 or more.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00497120

Contact: Wilfried De Backer, MD PhD +32 3 821 34 47 wilfried.debacker@ua.ac.be

University Hospital Antwerp Recruiting
Edegem, Antwerp, Belgium, 2650
Contact: Olivier M Vanderveken, MD       olivier.vanderveken@uza.be   
Sub-Investigator: Olivier M Vanderveken, MD         
Sub-Investigator: Annick Devolder, MD         
Sponsors and Collaborators
University Hospital, Antwerp
Principal Investigator: Wilfried De Backer, MD, PhD University Hospital, Antwerp
  More Information

ClinicalTrials.gov Identifier: NCT00497120     History of Changes
Other Study ID Numbers: EC 2/27/99 
Study First Received: July 4, 2007
Last Updated: July 5, 2007
Health Authority: Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment

Keywords provided by University Hospital, Antwerp:
sleep apnea
daytime sleepiness
upper airway

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Nervous System Diseases
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016